期刊文献+

血管紧张素受体拮抗剂治疗心力衰竭的研究进展 被引量:1

下载PDF
导出
摘要 已经有较多血管紧张素Ⅱ受体拮抗剂(angiotensinⅡreceptor blocker,ARB)治疗心力衰竭的大规模临床研究证实,ARB能够降低心力衰竭的发病率和病死率。其机制主要是ARB选择性阻滞了AngⅡ与AT_1。受体的结合,预防和改善左室重构,纠正心力衰竭时的神经激素异常。目前倾向于对不能耐受血管紧张素转换酶抑制剂(AcEI)者改为ARB;对收缩功能不全心力衰竭首选治疗是ACEI,如果不能耐受ACEI,改为ARB。但已经有研究结果证实ARB可以作为首选应用于心力衰竭的治疗,而并非仅仅是ACEI的替代。评价ARB在心力衰竭治疗中的地位时面临的主要问题是ARB能否取代ACEI用于收缩性心力衰竭首选治疗,以及ARB与ACEI的联合使用。目前存在不同观点,仍需要更多的和设计更为合理的循证医学证据。可以预见ARB将成为治疗心力衰竭的基本药物之一。
作者 曹雪滨 曹蕊
机构地区 解放军
出处 《临床误诊误治》 2006年第4期1-4,共4页 Clinical Misdiagnosis & Mistherapy
  • 相关文献

参考文献14

  • 1Crozier I,Ikram H,Awan N,et al.Losartan in heart failure.Hemodynamic effects and tolerability[J].Circulation,1995,91:691-697.
  • 2Hikosaka M,Yuasa F,Yuyama R,et al.Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure[J].J Cardiovasc Pharmacol,2002,40:875-880.
  • 3Thai H,Wollmuth J,Goldman S,et al.AT1 receptor blockade improves vasorelaxation in heart failure by up regulation of endothelial nitricoxide synthase via activation of the AT2 receptor[J].J Pharmacol Exp Ther,2003,307:1171-1178.
  • 4Sakatay Y,Yamamoto K,Mano T,et al.AngiotensinⅡtype 1 receptor blockade prevents diastolic heart failure through modulation of Ca2+regulatory proteins and extracellular matrix[J].J Hypertens,2003,21:1737-1745.
  • 5Wong M,Staszewsky L,Latini R,et al.Valsartan benefits left ventricular structure and function in heart failure:Val-HeFT echocardiographic study[J].J Am Coll Cardiol,2002,40:970-975.
  • 6Kasama S,Toyama T,Kumakura H,et al.Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction[J].J Am Coll Cardiol,2005,45:661-667.
  • 7Riegger GA,Bouzo H,Petr P,et al.Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil[J].Circulation 1999,100:2224-2230.
  • 8Scott D,Solomon MD,Duolao Wang phD,et al.Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients The Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program[J].Circulation,2004,110:2180-2183.
  • 9Dickstein K,Kjekshus J.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial[J].Lancet,2002,360:752-760.
  • 10Pfeffer MA,McMurray JJ,Velazquez EJ,et al.Valsartan,captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction,or both[J].N Engl J Med,2003,349:1893-1906.

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部